Deja vu: FDA committee recommends Pfizer’s RSV shot despite known risks
Thursday March 2, 2023
Do we have to wait for two years’ worth of death and injury reports from the incoming RSV shots before we begin warning against them? Or have we learned anything from Pfizer and Moderna’s fraudulent trials on COVID?
Last week, the CDC’s Advisory Committee on Immunization Practices met to discuss the future framework of a number of vaccines. Of course, all of them were deemed safe enough to continue, although a number of shocking nuggets of data were revealed with the understanding that the public will never discover this information. According to FDA briefing documents, two people in the Pfizer RSV trial for those over 60 years old experienced the dangerous form of neuropathy known as Guillain-Barré syndrome. The rate was 1 in 9,000, which is bad enough, but we’ve seen from COVID that GBS is a fairly common reaction, and Bell’s palsy, a similar form of neuropathy, has racked up 16,755 entries in VAERS.
This is particularly concerning because in the Phase 1/2 trial for Pfizer’s RSV shot, among a younger cohort of 18- to 49-year-olds, the trial reports one death among the 164 participants in the group getting 120 micrograms (the dose now recommended for seniors). “One participant in the 120-µg RSVpreF group died within 12 months postvaccination 1 due to toxicity to various agents (quetiapine and amlodipine) that was considered not vaccine-related,” reports Pfizer. After everything we experienced with the fraud from the COVID trials, are we really to trust that a disclosed death due to toxicity was somehow confirmed not to be related to the vaccine?
GlaxoSmithKline already had to pause its RSV trial for pregnant women due to safety concerns. According to Pharma Intelligence, one death occurred in the trial, attributed to acute disseminated encephalomyelitis 22 days after vaccination, “considered by both the study investigator and FDA to potentially be related to the vaccine.” Meanwhile, GSK’s shot for elderly people appears to be right on track, even though, as Dr. Meyrl Nass reports, ACIP participants raised questions about the fact that this shot “can overstimulate the immune system, which is why it is only used for the elderly or immunocompromised.” How in the world can anything that “overstimulates” the immune system be approved for anyone of any age after everything we’ve seen with COVID and all of the problems with neuropathies and autoimmune disorders stemming from this overstimulation?